Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic ...

This milestone is a pivotal step in enabling the commencement of a Phase 2/3 clinical trial within the HEALEY ALS Platform Trial framework. The FDA has a period of 30 days to review the IND ...

The drug was investigated as part of the HEALEY ALS Platform trial. Its primary endpoints were to assess changes in disease severity over time using the ALS Functional Rating Scale-Revised ...

Reducing the cost of research by 30%, decreasing trial time by 50%, and increasing patient participation by 67%, the HEALEY ALS Platform Trial is a vital step toward finding new ALS therapies. The ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

according to topline results from the Healey ALS platform trial. Fosigotifator did not demonstrate a significant effect on disease progression, combining function and mortality measures ...

Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...